Pratia Onkologia Katowice

The trials here

What the 30 trials at this site are about, from their registry records.

Conditions

• Myeloproliferative neoplasms8 trials
• Multiple myeloma6 trials
• Chronic lymphocytic leukaemia4 trials
• Myelodysplastic syndromes4 trials
• Acute lymphoblastic leukaemia2 trials
• Chronic myeloid leukaemia2 trials
• Diffuse large B-cell lymphoma2 trials
• Follicular lymphoma2 trials
• Immune thrombocytopenia (ITP)2 trials
• Lung cancer2 trials
• Mantle cell lymphoma2 trials
• Acute myeloid leukaemia1 trial
• and 3 more

Phase

• Phase 318 trials
• Phase 26 trials
• Phase 1/22 trials
• Phase 42 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Recruiting14 trials
• Active, not recruiting9 trials
• Completed3 trials
• Not yet recruiting3 trials
• Terminated1 trial

Lead sponsor

• Pfizer3 trials
• Bristol-Myers Squibb2 trials
• Janssen Research & Development, LLC2 trials
• Karyopharm Therapeutics Inc2 trials
• Novartis Pharmaceuticals2 trials
• and 18 more

Running trials

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source

  Contact: Sebastian Grosicki (principal investigator)

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  NCT07582432· Phase 3· Grifols Biologicals, LLC· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· Phase 4· Eli Lilly and Company· Source

  Contact: Sebastian Grosicki (principal investigator)

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

  NCT07095127· Phase 2· Nuvig Therapeutics, Inc.· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Recruiting

  Study of Olverembatinib (HQP1351) in Patients With CML-CP

  NCT06423911· Phase 3· Ascentage Pharma Group Inc.· Source

• Recruiting

  Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

  NCT06191263· Phase 2· Ryvu Therapeutics SA· Source

  Contact: Sebastian Grosicki, Prof. (principal investigator)

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS

  2022-500430-29-00· Phase 3· Celgene Corp.· Source

• Active, not recruiting

  A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

  NCT06045689· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Asciminib Roll-over Study

  NCT04877522· Phase 4· Novartis Pharmaceuticals· Source

• Recruiting

  Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

  NCT05280509· Phase 1/2· Telios Pharma, Inc.· Source

  Contact: John Mei

• Recruiting

  A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT05131022· Phase 1· Nurix Therapeutics, Inc.· Source

• Recruiting

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236· Phase 3· Pfizer· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

  NCT04562870· Phase 2· Karyopharm Therapeutics Inc· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Genmab· Source

• Active, not recruiting

  A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

  NCT04002297· Phase 3· BeOne Medicines· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia4 recruiting
• Multiple myeloma4 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Follicular lymphoma2 recruiting
• Lung cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Mantle cell lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· NS Pharma, Inc.· Source

• Active, not recruiting

  Study to Assess SLN124 in Patients With Polycythemia Vera

  NCT05499013· Phase 1/2· Silence Therapeutics plc· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

  NCT05469737· Phase 2/3· Bristol-Myers Squibb· Source

• Terminated

  Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  NCT05070845· Phase 2· Pfizer· Source